Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Common Equity (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Common Equity for 6 consecutive years, with $8.8 million as the latest value for Q3 2018.

  • Quarterly Common Equity fell 9.85% to $8.8 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Sep 2018, down 9.85% year-over-year, with the annual reading at $24.3 million for FY2017, 150.37% up from the prior year.
  • Common Equity hit $8.8 million in Q3 2018 for Armata Pharmaceuticals, down from $11.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $24.3 million in Q4 2017 to a low of -$34.0 million in Q1 2014.
  • Historically, Common Equity has averaged $7.3 million across 5 years, with a median of $9.8 million in 2017.
  • Biggest five-year swings in Common Equity: soared 389.24% in 2016 and later crashed 54.1% in 2017.
  • Year by year, Common Equity stood at $3.4 million in 2014, then skyrocketed by 269.92% to $12.7 million in 2015, then decreased by 23.53% to $9.7 million in 2016, then skyrocketed by 150.37% to $24.3 million in 2017, then tumbled by 63.87% to $8.8 million in 2018.
  • Business Quant data shows Common Equity for ARMP at $8.8 million in Q3 2018, $11.6 million in Q2 2018, and $14.7 million in Q1 2018.